TY - JOUR
T1 - Calcium channel antagonists
T2 - Morbidity and mortality - What's the evidence?
AU - Straka, Robert J
AU - Swanson, Amy L.
AU - Parra, David
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1998/4/1
Y1 - 1998/4/1
N2 - Recent studies have shown an association between the use of calcium channel antagonists for the treatment of hypertension and an increased risk of myocardial infarction, gastrointestinal hemorrhage and cancer. The interpretation of the results of these studies and their application to clinical practice requires an understanding of study design constraints, conflicting results and limitations in extrapolating study findings to other dosage strengths, formulations or agents within the calcium channel antagonist class. A review and critique of these studies provides background information on the controversial subject of using calcium channel antagonists for the treatment of hypertension. Despite the limitations of these studies, clinicians may want to select other classes of agents, including diuretics and beta blockers, as first-line therapy until the morbidity and mortality effects related to the use of calcium channel antagonists are clearly known.
AB - Recent studies have shown an association between the use of calcium channel antagonists for the treatment of hypertension and an increased risk of myocardial infarction, gastrointestinal hemorrhage and cancer. The interpretation of the results of these studies and their application to clinical practice requires an understanding of study design constraints, conflicting results and limitations in extrapolating study findings to other dosage strengths, formulations or agents within the calcium channel antagonist class. A review and critique of these studies provides background information on the controversial subject of using calcium channel antagonists for the treatment of hypertension. Despite the limitations of these studies, clinicians may want to select other classes of agents, including diuretics and beta blockers, as first-line therapy until the morbidity and mortality effects related to the use of calcium channel antagonists are clearly known.
UR - http://www.scopus.com/inward/record.url?scp=0032054024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032054024&partnerID=8YFLogxK
M3 - Review article
C2 - 9556644
AN - SCOPUS:0032054024
SN - 0002-838X
VL - 57
SP - 1551
EP - 1560
JO - American family physician
JF - American family physician
IS - 7
ER -